BOSTON, Jan. 29, 2024 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company aspiring to treat human diseases by rewriting RNA, today announced that the U.S. Food and Drug Administration (FDA) ...
Ascidian Therapeutics, a company developing RNA rewriting (or RNA exon editing) technology, announced a research collaboration and licensing agreement with Roche for the discovery and development of ...
Combines RNA Exon Editors with next generation CNS delivery capabilities of Roche to develop novel medicines for difficult to treat neurological diseases BOSTON, June 18, 2024 /PRNewswire/ -- Ascidian ...
Compelling translational insights underscore therapeutic potential of Ascidian's lead ACDN-01 program for people living with Stargardt disease and other ABCA4 retinopathies ACDN-01 awarded Rare ...
Roche has tapped the biotech start-up Ascidian Therapeutics to discover and develop RNA exon–editing medicines. Ascidian “rewrites” RNA by editing exons, parts of genes that form the nucleic acid, ...
RNA could be considered DNA’s younger sibling. From the very beginning, RNA’s milestones came later and attracted less attention than DNA’s milestones. For example, the discovery of DNA’s structure ...
In the genome, genes that code for protein are often divided into sections called exons, which are separated by spacers called introns. When a region of DNA is transcribed into messenger RNA (mRNA) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback